The Biostatistics Core under the Directorship of Dr. Phyllis Gimotty has vast biostatistical experience, especially in cancer biology and therapy. The goals of the Biostatistics Core are to provide biostatistical expertise to Program Project investigators and their personnel, and in collaboration with these investigators to use statistical models and other statistical techniques to better understand the etiology and progression of esophageal cancer. The Biostatistics Core faculty and staff have vast experience in cancer research and extensive experience with the proposed statistical methodologies and their application to the research studies proposed in this Program Project. They will provide expertise in the following areas to support its research objectives: (1) statistical methods to study associations among gene-related factors and/or among associated protein-related factors, as well as factors that influence tumor growth in different biological models;(2) statistical design and evaluation strategies to assess the impact of experimental interventions in genes on relevant biological outcomes (cell proliferation and apoptosis, tumor growth and development, therapeutic response);and (3) statistical decision making tools to make scientifically valid statements related to key scientific hypotheses. The Biostatistics Core members will collaborate with project investigators to interpret and synthesize study findings, collaborate on the preparation of manuscripts and maintain a database library linking all of the analytic databases. These collaborations will ensure that the projects continue to have high quality study designs and statistical analysis plans, which will provide an outstanding foundation for statistical models and inferences made from the experimental data. This Core is dynamic in responding to evolving P01 needs, anticipating future P01 directions, and integrating new statistical methodologies and models,

Public Health Relevance

(Seeinstructions): This Core is of vital importance to ensure that the experimental design and data analyses within the Projects are done in a rigorous, integrated fashion, and to forge new directions in the translational components of the Program Project. This Core has a wealth of experience in cancer research that is used by the Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098101-09
Application #
8380744
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
9
Fiscal Year
2012
Total Cost
$94,472
Indirect Cost
$28,068
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Campbell, Joshua D; Yau, Christina; Bowlby, Reanne et al. (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23:194-212.e6
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478
Giroux, VĂ©ronique; Stephan, Julien; Chatterji, Priya et al. (2018) Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating. Stem Cell Reports 10:1947-1958
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Bockorny, Bruno; Rusan, Maria; Chen, Wankun et al. (2018) RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. Mol Cancer Ther 17:1526-1539
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Karakasheva, Tatiana A; Dominguez, George A; Hashimoto, Ayumi et al. (2018) CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3:

Showing the most recent 10 out of 173 publications